---
title: "KURA.US (KURA.US) — 相關新聞"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/KURA.US/news.md"
symbol: "KURA.US"
name: "KURA.US"
parent: "https://longbridge.com/zh-HK/quote/KURA.US.md"
datetime: "2026-03-13T07:47:48.760Z"
locales:
  - [en](https://longbridge.com/en/quote/KURA.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/KURA.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/KURA.US/news.md)
---

> 支持的語言: [English](https://longbridge.com/en/quote/KURA.US/news.md) | [简体中文](https://longbridge.com/zh-CN/quote/KURA.US/news.md)


# KURA.US (KURA.US) — 相關新聞

### [Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://longbridge.com/zh-HK/news/278634920.md)
*2026-03-11T00:47:34.000Z*
> On March 2, 2026, Kura Oncology, Inc. (Nasdaq: KURA) announced the granting of inducement awards by the Compensation Com

### [Kura Oncology (KURA) Receives a Hold from Guggenheim](https://longbridge.com/zh-HK/news/278219428.md)
*2026-03-07T13:46:47.000Z*
> In a report released yesterday, from Guggenheim maintained a Hold rating on Kura Oncology. The company’s shares closed y

### [Kura Oncology (KURA) Deep FY 2025 Loss Reinforces Bearish Profitability Concerns](https://longbridge.com/zh-HK/news/278057424.md)
*2026-03-06T08:36:51.000Z*
> Kura Oncology (KURA) reported a significant net loss of $81 million for Q4 FY 2025, with a basic EPS loss of $0.92. The 

### [Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KURA Stock News](https://longbridge.com/zh-HK/news/278102136.md)
*2026-03-06T04:30:00.000Z*
> Kura Oncology, Inc. announced the grant of inducement awards under Nasdaq Listing Rule 5635(c)(4) on March 2, 2026. The 

### [Kura Oncology Q4 net loss widens on higher R&D spend](https://longbridge.com/zh-HK/news/277928340.md)
*2026-03-05T11:41:20.000Z*
### [Early Komzifti Traction and Clinical Catalysts Underpin Buy Rating and 2028 Growth Outlook](https://longbridge.com/zh-HK/news/277979016.md)
*2026-03-05T18:45:23.000Z*
> TD Cowen analyst Phil Nadeau has maintained a Buy rating on KURA stock, citing early commercial traction of Komzifti and